Pharmacokinetics, Pharmacodynamics, and Safety of Etrolizumab in Children With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease: Results from a Phase 1 Randomized Trial

BACKGROUND: Etrolizumab, a humanized anti-β7 antibody, has not been studied in children. Here, we evaluate the pharmacokinetics, pharmacodynamics, and safety of etrolizumab in children with inflammatory bowel disease. METHODS: Patients age 4 to 17 years with moderately to severely active ulcerative...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Wenhui, Scalori, Astrid, Fuh, Franklin, McBride, Jacqueline, She, Gaohong, Kierkus, Jaroslaw, Korczowksi, Bartosz, Li, Regan, Abouhossein, Mariam, Kadva, Alysha, Park, K T, Tang, Meina Tao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434437/
https://www.ncbi.nlm.nih.gov/pubmed/34849918
http://dx.doi.org/10.1093/ibd/izab275

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9434437/
https://www.ncbi.nlm.nih.gov/pubmed/34849918
http://dx.doi.org/10.1093/ibd/izab275

Ejemplares similares